Clinical Utility of ALK Fusion Detection by Liquid Biopsy
Clinical Utility of ALK Fusion Detection by Liquid Biopsy Cell-free DNA NGS detects common and novel ALK fusions in...
Category: Agilent Dako
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer MSK and...
Agilent Announces Cash Dividend of 19.4 Cents per Share
Agilent Announces Cash Dividend of 19.4 Cents per Share Agilent Technologies, Inc. (NYSE: A) today announced that a...
Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection
Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection Agilent...
Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer
Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer Agilent Technologies Inc. (NYSE: A), today...
Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics Resolution...
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC) Agilent...
Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies Agilent Technologies Inc. (NYSE: A) today announced...
Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies
Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies Agilent Technologies Inc. (NYSE: A)...
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results Highlights: Revenue of $1.55 billion represents an...
Page 3 of 4
